Clinical Trial

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Study acronym: CheckMate-1533
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-15
notable Trial sites reduced: 48 -> 38 locations 2026-05-15
Trial Details
NCT Number NCT06946797
Lead Sponsor Bristol-Myers Squibb
Conditions Non-Small Cell Lung Cancer
Enrollment 76 participants
Start Date 2025-09-19
Primary Completion 2027-02-05 (estimated)
Study Completion 2028-10-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-14